Justice Moshinsky held that NOCO’s position was to be preferred, finding that the relevant date for assessing the best method “knowledge element” was the filing date of the earliest complete ...

As the patent for semaglutide nears its end, Novo Nordisk's dominance in the weight-loss market is being challenged. The ...